

## **Eurofins Medinet laboratory in Denver expands and relocates to new facility**

**November, 2008**

In response to a fast growing demand from our industry, Eurofins Medinet has expanded and relocated its Bioanalytical Center of Excellence in Denver, Colorado to a larger and dedicated laboratory facility building. Complementing the European Bioanalytical Center of Excellence in Breda, the Netherlands, the laboratory offers a comprehensive range of innovative specialized services including pharmacokinetics, toxicokinetics, bioanalysis for pre-clinical and clinical studies, discovery, development and analysis of biomarkers, quantification of endogenous compounds such as isoprostanes and steroid hormones, proteomics and metabolic profiling.

The strength of Eurofins Medinet Denver lies in its “omics-based” approach to molecular marker discovery, qualification and quantification. By utilizing metabolomic and proteomic techniques Eurofins Medinet Denver determines the relevance of changes in the metabolome and proteome to explore the mechanism of action of a therapeutic and its therapeutic and/or toxic effects.

Eurofins Medinet Denver commenced its Bioanalytical Center of Excellence with professor Uwe Christians and his dedicated team in May 2007. Located in the Fitzsimons Biotech Park next to the University of Colorado, Eurofins Medinet Denver offers its services either in a local setting, or in close conjunction with Eurofins Medinet's Central Laboratory in Washington DC or even in a global approach with the European Bioanalytical Center of Excellence in Breda, the Netherlands. Eurofins Medinet Denver is lead by Dr. Jamie Bendrick-Peart, Chief Operations Officer and Dr. Jost Klawitter, Chief Technology Officer.

**For further information please visit [www.eurofinsmedinet.com](http://www.eurofinsmedinet.com) or contact:**

Eurofins Medinet Denver  
Jamie Bendrick-Peart, COO  
BioScience East  
1999 North Fitzsimons Parkway, Suite 100  
Aurora Colorado 80045  
Phone: +1 720 961 4488  
[Jamie.Bendrick-Peart@eurofinsmedinet.com](mailto:Jamie.Bendrick-Peart@eurofinsmedinet.com)

Investor Relations  
Phone: +32-2-769 7383  
E-mail: [ir@eurofins.com](mailto:ir@eurofins.com)

**Notes for the editor:****Eurofins – a global leader in bio-analysis**

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.

With about 7,000 staff in more than 150 laboratories across 29 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff.

The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).

**About Eurofins Medinet**

Eurofins Medinet provides a full range of central laboratory testing services including safety parameters, biomarker development and analysis, and specialized testing in bioanalysis, pharmacokinetics, microbiology and genomics using its fully standardized and accredited central laboratories in the Netherlands, USA (two laboratories), France, Singapore and China.

**Important disclaimer:**

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.